Bristol Myers Squibb Provides Update on Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel)

PRINCETON, N.J.--(BUSINESS WIRE)-- May 6, 2020 Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the biologics license application (BLA) for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news